WASHINGTON, DC – U.S. House Energy and Commerce Committee Chairman Fred Upton (R-MI) issued the following statement this evening following President Obama’s State of the Union address:
WASHINGTON, DC – House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Communications and Technology Subcommittee Chairman Greg Walden (R-OR) today welcomed reports that CTIA – The Wireless Association and two Los Angeles broadcasters, KLCS and KJLA, are seeking permission from the FCC to engage in a first-of-its-kind broadcast channel sharing arrangement. The trial would test the feasibility of two broadcast stations sharing a single 6 MHz broadcast channel, thus potentially freeing up spectrum for auction.
WASHINGTON, DC – The House Energy and Commerce Committee today approved two bipartisan bills as part of its ongoing pursuit of an all-of-the-above energy strategy. H.R. 2126, the Better Buildings Act, advanced by voice vote and H.R. 3826, the Electricity Security and Affordability Act, passed by a vote of 29 to 19.
Presidential Ally Moran on the State of Obamacare: “I don't think we're going to get enough young people signing up to make this bill work”
While full construction of the Keystone XL pipeline continues to be blocked by red tape in Washington, the southern leg of the pipeline began pumping oil today. This interstate portion of the project, known as the Gulf Coast Project, was actually endorsed by President Obama in March of 2012, but his claims to support an “all-of-the-above” energy strategy have fallen short.
House Energy and Commerce Committee Leaders Express Concerns, Raise Questions Regarding FDA’s Proposed Change to Generic Drug Labeling PolicyJanuary 22, 2014 | Press Release
WASHINGTON, DC – House Energy and Commerce Committee Chairman Fred Upton (R-MI), today led a group of House and Senate Republican lawmakers in sending a letter to Food and Drug Administration (FDA) Commissioner Margaret Hamburg expressing concerns about the FDA’s proposed regulation to allow generic drug companies to unilaterally change their drug labeling information, saying “such a rule would conflict directly with the statute, thwart the law’s purposes a